➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: July 27, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,293,742

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,293,742 protect, and when does it expire?

Patent 8,293,742 protects LUMIFY and is included in one NDA.

This patent has thirty-seven patent family members in sixteen countries.

Summary for Patent: 8,293,742
Title:Preferential vasoconstriction compositions and methods of use
Abstract: The invention generally relates to compositions and methods for preferential vasoconstriction of smaller blood vessels relative to larger blood vessels. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
Inventor(s): Horn; Gerald (Deerfield, IL)
Assignee: Alpha Synergy Development, Inc. (Dana Point, CA)
Application Number:12/460,941
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,293,742

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch And Lomb Inc LUMIFY brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 208144-001 Dec 22, 2017 OTC Yes Yes ⤷  Try it Free ⤷  Try it Free RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,293,742

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil 112016004054 ⤷  Try it Free
Canada 2732521 ⤷  Try it Free
Canada 2782817 ⤷  Try it Free
Canada 2832953 ⤷  Try it Free
Canada 2865593 ⤷  Try it Free
Cyprus 1115727 ⤷  Try it Free
Denmark 2320911 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.